G protein‐coupled receptor 84 controls osteoclastogenesis through inhibition of NF‐κB and MAPK signaling pathways
暂无分享,去创建一个
Y. Yoon | H. Lee | Hyun-Ju Kim | S. Seong | W. Kang | Seungil Cho | H. Yoon | Ji-Wan Park
[1] Seung Hun Lee,et al. Free Fatty Acid Receptor 4 (GPR120) Stimulates Bone Formation and Suppresses Bone Resorption in the Presence of Elevated n-3 Fatty Acid Levels. , 2016, Endocrinology.
[2] Shin-Yoon Kim,et al. G Protein‐Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function , 2016, Journal of cellular physiology.
[3] M. Tremblay,et al. GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s disease , 2015, Brain, Behavior, and Immunity.
[4] Mathew W. Wright,et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors , 2015, Pharmacological Reviews.
[5] Jianlong Wang,et al. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis. , 2014, Blood.
[6] T. Oda,et al. Medium-chain Fatty Acid-sensing Receptor, GPR84, Is a Proinflammatory Receptor , 2013, The Journal of Biological Chemistry.
[7] T. Alquier,et al. The Free Fatty Acid Receptor G Protein-coupled Receptor 40 (GPR40) Protects from Bone Loss through Inhibition of Osteoclast Differentiation* , 2013, The Journal of Biological Chemistry.
[8] D. Oh,et al. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity , 2011, Current opinion in clinical nutrition and metabolic care.
[9] S. Watkins,et al. GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects , 2010, Cell.
[10] K. Mackie,et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.
[11] Jian Luo,et al. Regulation of bone formation and remodeling by G-protein-coupled receptor 48 , 2009, Development.
[12] A. Su,et al. Expression analysis of G Protein-Coupled Receptors in mouse macrophages , 2008, Immunome research.
[13] H. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[14] S. Teitelbaum,et al. The osteoclast: friend or foe? , 2008, Annual review of pathology.
[15] E. Wagner,et al. NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.
[16] C. Bouchard,et al. G protein‐coupled receptor 84, a microglia‐associated protein expressed in neuroinflammatory conditions , 2007, Glia.
[17] S. Teitelbaum. Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.
[18] Hiroshi Takayanagi,et al. The molecular understanding of osteoclast differentiation. , 2007, Bone.
[19] H. Tian,et al. Medium-chain Fatty Acids as Ligands for Orphan G Protein-coupled Receptor GPR84* , 2006, Journal of Biological Chemistry.
[20] Y. Kadono,et al. Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.
[21] W. Richards,et al. The G-Protein-Coupled Receptor GPR103 Regulates Bone Formation , 2006, Molecular and Cellular Biology.
[22] C. Venkataraman,et al. The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. , 2005, Immunology letters.
[23] H. Aburatani,et al. Nuclear Factor of Activated T-cells (NFAT) Rescues Osteoclastogenesis in Precursors Lacking c-Fos* , 2004, Journal of Biological Chemistry.
[24] S. Teitelbaum,et al. Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.
[25] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[26] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[27] S. Yousefi,et al. Cloning and expression analysis of a novel G‐protein‐coupled receptor selectively expressed on granulocytes , 2001, Journal of leukocyte biology.
[28] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[29] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] Ulrich Siebenlist,et al. Requirement for NF-κB in osteoclast and B-cell development , 1997 .
[31] E. Wagner,et al. Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.
[32] B. Spiegelman,et al. Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.
[33] J. Caamaño,et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. , 1997, Nature medicine.
[34] A. Leonardi,et al. Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.